alternative trial designs based on tumor genetics/pathway ...alternative trial designs based on...
TRANSCRIPT
![Page 1: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/1.jpg)
Panel One:
Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics
![Page 2: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/2.jpg)
Alternative Trial Designs Based on Tumor Genetics and/or Pathway
Characteristics Instead of HistologyGeorge D. Demetri, MDGeorge D. Demetri, MD
Senior Vice President for Experimental TherapeuticsSenior Vice President for Experimental TherapeuticsDanaDana--Farber Cancer InstituteFarber Cancer Institute
Ludwig Center at DanaLudwig Center at Dana--Farber/Harvard Cancer CenterFarber/Harvard Cancer CenterHarvard Medical SchoolHarvard Medical SchoolBoston, MassachusettsBoston, [email protected]@partners.org
![Page 3: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/3.jpg)
We now have better understanding of pathways in cancer cells
Adapted from Dawelbait G et al. Bioinformatics 2007;23:i115-i124
Cell Membrane
Nucleus
![Page 4: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/4.jpg)
Mapping relevant interactions and pathways in cancer cells
Adapted from Dawelbait G et al. Bioinformatics 2007;23:i115-i124Hanahan and Weinberg, Cell 2011
![Page 5: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/5.jpg)
![Page 6: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/6.jpg)
TUMOR TYPE 1
TUMOR TYPE 2
TUMOR TYPE 3
BREAST CANCER
PANCREAS CA
…SARCOMAS…
![Page 7: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/7.jpg)
Cancers are often Cancers are often managed based on where managed based on where
the first tumor startsthe first tumor starts
![Page 8: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/8.jpg)
PANCREAS CA
BREAST CANCER
SARCOMAS
![Page 9: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/9.jpg)
What is the What is the ““standard processstandard process””for anticancer drug for anticancer drug
development?development?
![Page 10: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/10.jpg)
DRUG “G”PANCREAS CA
FDA Approval
Change in Practice
BREAST CANCER
SARCOMAS
YEARS
MORE YEARS
![Page 11: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/11.jpg)
How can we accelerateHow can we acceleratethis process to bringthis process to bring
the right new drugs to the right new drugs to the right patientsthe right patientsas efficiently as as efficiently as
possible?possible?
![Page 12: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/12.jpg)
A MOLECULAR TARGETTHAT DRIVES CANCER
![Page 13: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/13.jpg)
LEUKEMIA
GIST / SARCOMA
FDA Approval2001
2002
Blood Cancer #2(ALL)
SARCOMA #2(DFSP)
Mast Cell Cancer
HypereosinophilCancer
Pre-leukemia (MDS / MPD)
2009
![Page 14: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/14.jpg)
LEUKEMIA
GIST / SARCOMA
MELANOMA
![Page 15: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/15.jpg)
Identifying challengesIdentifying challengesto the success ofto the success of
this processthis process
![Page 16: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/16.jpg)
Challenge # 1:Challenge # 1:
Measuring the value ofMeasuring the value oftumor cell origin (histology)tumor cell origin (histology)while aggregating cancerswhile aggregating cancers
by molecular targetby molecular target
![Page 17: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/17.jpg)
Challenge # 2:Challenge # 2:
Working with regulatory Working with regulatory authoritiesauthorities
to agree on transparent metricsto agree on transparent metricsfor success of new trial designs for success of new trial designs
across cancer typesacross cancer types
![Page 18: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/18.jpg)
Challenge # 3:Challenge # 3:
Biology and complexity Biology and complexity of cancerof cancer
![Page 19: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/19.jpg)
![Page 20: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/20.jpg)
Drug Therapy
![Page 21: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/21.jpg)
Patient A Treatment
Patient A Treatment
![Page 22: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/22.jpg)
Different perspectivesDifferent perspectivesin addressing this today:in addressing this today:
Patient and Advocate PerspectivePatient and Advocate Perspective::Josh Josh SommerSommer ((ChordomaChordoma Foundation)Foundation)
NCI perspective: Dr. James NCI perspective: Dr. James DoroshowDoroshow
A Modest Proposal with Industry Support:A Modest Proposal with Industry Support:Dr. Perry Dr. Perry NisenNisen ((GlaxoSmithGlaxoSmith Kline)Kline)
FDA perspective: Dr. Robert BeckerFDA perspective: Dr. Robert Becker
Regulatory Overview: Dr. Janet Woodcock Regulatory Overview: Dr. Janet Woodcock (FDA)(FDA)
![Page 23: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/23.jpg)
Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics
Josh Sommer, Patient AdvocateThe Chordoma Foundation
![Page 24: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/24.jpg)
Friends of Cancer Research & Brookings Institution Conference on Clinical Cancer Research
November 10, 2011
Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics Instead of Histology
James H. Doroshow, M.D.Deputy Director for Clinical and Translational Research
National Cancer Institute
![Page 25: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/25.jpg)
Phase II Cancer Trials: Historical Context
• 1985-2005: Dogma: Two-stage Fleming or Simon Designs; occasional randomized phase II’s Purpose: Estimate an objective response rate of
patients with a specified tumor type to a particular drug
At least two trials with ‘adequate’ numbers of patients in each major tumor type (N=14-25)
All patents entered must have measurable disease All patients must have maximum performance status
and minimum prior therapy If no objective responses seen in 25 patients, drop Rx Large phase II studies to define levels of activity are
generally not indicated
R. Wittes et al., Cancer Treat. Rep. 70: 1105, ‘86
![Page 26: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/26.jpg)
0200400600800
1000120014001600
1965 1975 1985 1995 2005
Published Phase II Cancer Treatment Trials:1965-2005
Exclusive Use ofHistology-Based
Ph II Designs
![Page 27: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/27.jpg)
Kola & Landis; Nature Reviews Drug Discovery 2004
•70% of oncology drugs that enter Phase 2 fail to enter Phase 3
•59% of oncology drugs that enter Phase 3 fail
•Late stage failure leads to enormous risk
Rates of success for compounds entering first in man that progress to subsequent phase
Most Drugs Fail in Late Stages of Development-Particularly in Oncology
![Page 28: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/28.jpg)
Why Continue to Focus On A “Given Tumor Type”?
“Primary objective of phase II trials is to screen for preliminary evidence of efficacy in a given tumor type.”[Defined histologically;
J. Clin. Oncol. 26: 1346, 2008]
• Limited by modest availability of qualified molecular classifiers in therapeutics
• Limited by the complexity of performing evaluations of appropriate molecular markers in Phase II
• Limited by the lack of funding for these critical studies
![Page 29: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/29.jpg)
Target Inhibition as the Endpoint of a Phase II Trial: Proof of Concept Study of Oral Topotecan in Advanced
Solid Neoplasms Expressing HIF-1α
•Eligibility: HIF-1 +ve solid tumors of any histology (>10% of tumor cells by IHC)
•Treatment: Oral chronic topotecan (1.2 mg/m2 PO daily x 5 days x 2 wks q28 days)
•Primary endpoint: Inhibition of HIF-1α expression in tumor•Schema:
NCI-05-C-0186: Giovanni Melillo, MD PI
D1 D8 D29
BiopsyPETDCE-MRI
PETDCE-MRI
Biopsy PETDCE-MRICT
D36
CT
Cycle 1 Cycle 2
PD endpoints:• IHC (MVD, Glut-1)• mRNA expression (HIF-1 target genes,
VEGF, PGK-1, CAIX)• serum/plasma markers (VEGF, osteopontin)• CEP (circulating endothelial precursor cells)
![Page 30: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/30.jpg)
HIF-1α staining in patient #4 (breast cancer)
Baseline Biopsy After 2 Cycles of Topotecan
Accrual: 16 patients• 12 evaluable: 1 melanoma, 1 bladder, 1 breast, 2 ovarian ca., 1 SCLC,
1 bladder, 1 H/N, 4 CRC [PRs in SCLC, Ovarian cancer]• 4 not evaluable: 1 ASPS, 1 adrenal, 1 colon, 1 pancreas
Toxicities: myelosuppression, diarrhea (first 2 pts., at 1.6 mg/m2), well tolerated at 1.2 mg/m2
Pilot Study of Oral Topotecan in Advanced Solid Neoplasms Expressing HIF-1α
Clin. Cancer Res. 17: 5123-5131, 2011
![Page 31: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/31.jpg)
mRNA Expression of HIF-1α Downstream TargetsAfter Topotecan
Clin. Cancer Res. 17: 5123-5131, 2011
![Page 32: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/32.jpg)
Design Studies Based on Molecular Characteristics
Because:
• Current trial designs are not based on predictive, disease-specific preclinical models or (often) on predictive tumor biology
• Potentially more efficient: decrease regulatory and administrative burden—1 protocol; still requires appropriate sample sizes for each investigational group studied
• May speed up the evaluation of target effects of agent(s) across tumor types with potential to improve biomarker development/qualification
• May provide opportunity “borrow” efficacy and toxicity experience across all patients enrolled in the study
![Page 33: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/33.jpg)
Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics
Perry NisenOncology R & D, GlaxoSmithKline
![Page 34: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/34.jpg)
Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics
Bob BeckerCDRH, U.S. FDA
![Page 35: Alternative Trial Designs Based on Tumor Genetics/Pathway ...Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics. ... Alternative Trial Designs Based on Tumor](https://reader030.vdocument.in/reader030/viewer/2022040721/5e2d29d870f5da54f45a6ffa/html5/thumbnails/35.jpg)
Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics
Janet WoodcockCDER, U.S. FDA